CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment, 17996 [2017-07593]
Download as PDF
<![CDATA[
17996
Federal Register / Vol. 82, No. 71 / Friday, April 14, 2017 / Notices
sradovich on DSK3GMQ082PROD with NOTICES
Conducting Public Health Research in
South Africa; GH17–004, Conducting
Public Health Research Activities in
Egypt.
Summary: This publication corrects a
notice that was published in the Federal
Register on April 4, 2017, Volume 82,
Number 63, page 16403. The meeting
announcement, meeting date, and
matters for discussion should read as
follows:
The meeting announced below
concerns the Centers for Disease Control
and Prevention (CDC) initial review of
applications in response to Funding
Opportunity Announcements GH17–
002, Program Development and
Research to Establish and Evaluate
Innovative and Emerging Best Practices
in Clinical and Community Services
through the President’s Emergency Plan
for AIDS Relief (PEPFAR); and GH17–
003, Conducting Public Health Research
in South Africa.
Time and Date: 9:00 a.m.–2:00 p.m.,
EDT, April 25, 2017, Panel A (Closed).
Matters for Discussion: The meeting
will include the initial review,
discussion, and evaluation of
applications received in response to
‘‘Program Development and Research to
Establish and Evaluate Innovative and
Emerging Best Practices in Clinical and
Community Services through the
President’s Emergency Plan for AIDS
Relief (PEPFAR)’’, FOA GH17–002; and
‘‘Conducting Public Health Research in
South Africa’’, FOA GH17–003.
For Further Information Contact:
Hylan Shoob, Scientific Review Officer,
Center for Global Health (CGH) Science
Office, CGH, CDC, 1600 Clifton Road
NE., Mailstop D–69, Atlanta, Georgia
30033, Telephone: (404) 639–4796,
HSHOOB@CDC.GOV.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2017–07595 Filed 4–13–17; 8:45 am]
BILLING CODE 4163–18–P
VerDate Sep<11>2014
16:21 Apr 13, 2017
Jkt 241001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Health Resources and Services
Administration
CDC/HRSA Advisory Committee on
HIV, Viral Hepatitis and STD Prevention
and Treatment
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC) and the
Health Resources and Services
Administration (HRSA) announce the
following committee meeting.
Times and Dates: 8:30 a.m.–5:00 p.m.,
EDT, May 10, 2017; 8:30 a.m.–3:00 p.m.,
EDT, May 11, 2017.
Place: CDC Corporate Square,
Building 8, Conference Room 1–ABC, 8
Corporate Boulevard, Atlanta, Georgia
30329, Telephone: (404) 639–8317. The
meeting is also accessible by
teleconference. Toll-free number 1–877–
603–4228, Participant code: 42598858.
Status: Open to the public, limited
only by the space available. The meeting
room will accommodate approximately
100 people. Persons who desire to make
an oral statement, may request it at the
time of the public comment period on
May 10, 2017 at 4:30 p.m., EDT. Public
participation and ability to comment
will be limited to space and time as it
permits.
Purpose: This committee is charged
with advising the Director, CDC and the
Administrator, HRSA, regarding
activities related to prevention and
control of HIV/AIDS, Viral Hepatitis and
other STDs, the support of health care
services to persons living with HIV/
AIDS, and education of health
professionals and the public about HIV/
AIDS, Viral Hepatitis and other STDs.
Matters for Discussion: Agenda items
include the following topics: (1) HIV
transmission risk in the context of viral
suppression and antiretroviral therapy
(ART) use; (2) Update on Pre-Exposure
Prophylaxis (PrEP) utilization; (3)
Vulnerable youth at risk for HIV, STDs,
hepatitis, substance use and other
health outcomes; (4) Eliminating
hepatitis B and hepatitis C as public
health threats in the United States—
Setting Goals and Taking Action; and (5)
Updates from Workgroups. Agenda
items are subject to change as priorities
dictate.
Contact Person for More Information:
Margie Scott-Cseh, Centers for Disease
Control and Prevention, 1600 Clifton
Road NE., Mailstop E–07, Atlanta,
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
Georgia 30329, telephone (404) 639–
8317; Email: zkr7@cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
Notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2017–07593 Filed 4–13–17; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Healthcare Infection Control Practices
Advisory Committee (HICPAC)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC), National
Center for Emerging and Zoonotic
Infectious Diseases (NCEZID) announces
a meeting of the aforementioned
committee:
Time and Date: 1:00 p.m.–2:30 p.m.,
EDT, May 5, 2017.
Place: This meeting will be accessible
by teleconference. Toll-free +1 (888)
469–1070, Participant Code: 3132529.
Status: Open to the public limited
only by the availability of 200 telephone
ports. To register for this call, please go
to www.cdc.gov/hicpac.
Purpose: The Committee is charged
with providing advice and guidance to
the Director, Division of Healthcare
Quality Promotion, the Director,
National Center for Emerging and
Zoonotic Infectious Diseases (NCEZID),
the Director, CDC, the Secretary, Health
and Human Services regarding (1) the
practice of healthcare infection
prevention and control; (2) strategies for
surveillance, prevention, and control of
infections, antimicrobial resistance, and
related events in settings where
healthcare is provided; and (3) periodic
updating of CDC guidelines and other
policy statements regarding prevention
of healthcare-associated infections and
healthcare-related conditions.
Matters for Discussion: The agenda
will include a follow-up discussion on
the Draft Recommendation Update for
Chlorhexidine Impregnated Dressings.
Call materials will be made available to
the public no later than 2 business days
E:\FR\FM\14APN1.SGM
14APN1
]]>Agencies
[Federal Register Volume 82, Number 71 (Friday, April 14, 2017)]
[Notices]
[Page 17996]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-07593]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Health Resources and Services Administration
CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD
Prevention and Treatment
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463), the Centers for Disease Control and
Prevention (CDC) and the Health Resources and Services Administration
(HRSA) announce the following committee meeting.
Times and Dates: 8:30 a.m.-5:00 p.m., EDT, May 10, 2017; 8:30 a.m.-
3:00 p.m., EDT, May 11, 2017.
Place: CDC Corporate Square, Building 8, Conference Room 1-ABC, 8
Corporate Boulevard, Atlanta, Georgia 30329, Telephone: (404) 639-8317.
The meeting is also accessible by teleconference. Toll-free number 1-
877-603-4228, Participant code: 42598858.
Status: Open to the public, limited only by the space available.
The meeting room will accommodate approximately 100 people. Persons who
desire to make an oral statement, may request it at the time of the
public comment period on May 10, 2017 at 4:30 p.m., EDT. Public
participation and ability to comment will be limited to space and time
as it permits.
Purpose: This committee is charged with advising the Director, CDC
and the Administrator, HRSA, regarding activities related to prevention
and control of HIV/AIDS, Viral Hepatitis and other STDs, the support of
health care services to persons living with HIV/AIDS, and education of
health professionals and the public about HIV/AIDS, Viral Hepatitis and
other STDs.
Matters for Discussion: Agenda items include the following topics:
(1) HIV transmission risk in the context of viral suppression and
antiretroviral therapy (ART) use; (2) Update on Pre-Exposure
Prophylaxis (PrEP) utilization; (3) Vulnerable youth at risk for HIV,
STDs, hepatitis, substance use and other health outcomes; (4)
Eliminating hepatitis B and hepatitis C as public health threats in the
United States--Setting Goals and Taking Action; and (5) Updates from
Workgroups. Agenda items are subject to change as priorities dictate.
Contact Person for More Information: Margie Scott-Cseh, Centers for
Disease Control and Prevention, 1600 Clifton Road NE., Mailstop E-07,
Atlanta, Georgia 30329, telephone (404) 639-8317; Email: zkr7@cdc.gov.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register Notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and Prevention and the Agency
for Toxic Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. 2017-07593 Filed 4-13-17; 8:45 am]
BILLING CODE 4163-18-P
